NARA Discovery
Article Details
← Back to Search Results
Journal Article

Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine

Dimitris Repantis; Leonore Bovy; Kathrin Ohla; Simone Kühn; Martin Dresler
Psychopharmacology · Vol. 238, Issue 2 · pp. 441-451 · 2021

Abstract

Rational At all times humans have made attempts to improve their cognitive abilities by different means, among others, with the use of stimulants. Widely available stimulants such as caffeine, but also prescription substances such as methylphenidate and modafinil, are being used by healthy individuals to enhance cognitive performance. Objectives There is a lack of knowledge on the effects of prescription stimulants when taken by healthy individuals (as compared with patients) and especially on the effects of different substances across different cognitive domains. Methods We conducted a pilot study with three arms in which male participants received placebo and one of three stimulants (caffeine, methylphenidate, modafinil) and assessed cognitive performance with a test battery that captures various cognitive domains. Results Our study showed some moderate effects of the three stimulants tested. Methylphenidate had positive effects on self-reported fatigue as well as on declarative memory 24 hours after learning; caffeine had a positive effect on sustained attention; there was no significant effect of modafinil in any of the instruments of our test battery. All stimulants were well tolerated, and no trade-off negative effects on other cognitive domains were found. Conclusions The few observed significant positive effects of the tested stimulants were domain-specific and of rather low magnitude. The results can inform the use of stimulants for cognitive enhancement purposes as well as direct further research to investigate the effects of stimulants on specific cognitive domains that seem most promising, possibly by using tasks that are more demanding.

Bibliographic Information

JournalPsychopharmacology
PublisherSpringer
Publication Date2021-02-01
Publication Year2021
Volume238
Issue2
Pages441-451
Document TypeJournal Article
Print ISSN0033-3158
eISSN1432-2072
DOI10.1007/s00213-020-05691-w

Access Information

NARA Access Coverage1959-01-01~Current
Journal Homepagehttps://www.springer.com/journal/213
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.